AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01103063
Drug: Azithromycin plus chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
Trial: NCT00357617
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00969293
Drug: FOV2302 (Ecallantide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up.
Trial: NCT04413929
Drug: Ergoferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01254799
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Doxycycline capsules twice daily for 5 days
Trial: NCT01254799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily for 5 days
Trial: NCT00004031
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004031
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004031
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03078062
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single-dose of Normal saline during spinal anesthesia
Trial: NCT01413958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
Trial: NCT03124225
Drug: DMARD
RxNorm normalized name: Disease-modifying antirheumatic drug (DMARD)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03476044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
Trial: NCT00291720
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
Trial: NCT00291720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04482296
Drug: SSRI with Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (30 mg) once daily for 8 weeks SSRI
Trial: NCT00304785
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02420496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02065674
Drug: Abroma Augusta Q (mother tincture)
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 drops in 1 cup of water three times a day for 3 months
Trial: NCT01916304
Drug: Levothyroxine sodium new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine tablets
Trial: NCT04652128
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
Trial: NCT04652128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive a single infusion of physiological saline 100mL intravenously.
Trial: NCT03555526
Drug: Clarithromycin ER
RxNorm normalized name: Clarithromycin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clarithromycin 500mg, bid, for 7 days (day 8-14)
Trial: NCT03555526
Drug: tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tetracycline 500mg, qid, for 10 days
Trial: NCT01611324
Drug: Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
Trial: NCT01778166
Drug: Immuno-enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
Trial: NCT01778166
Drug: Standard early enteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
Trial: NCT00399334
Drug: antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT02753894
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01027793
Drug: Tretinoin cream 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
Trial: NCT04475328
Drug: AngongNiuhuang pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
Trial: NCT04475328
Drug: Placebo of AngongNiuhuang pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
Trial: NCT00745108
Drug: CE/MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
Trial: NCT00031460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
Trial: NCT02198794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to SD-809 will be administered per schedule specified in the arm.
Trial: NCT00192452
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03362515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00690638
Drug: PHX1149T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg
Trial: NCT00690638
Drug: PHX1149T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT00690638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02584309
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01114516
Drug: Indomethacin and antibiotics (cefazolin or clindamycin)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
Trial: NCT01035879
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets and capsule once daily
Trial: NCT00810121
Drug: ketoprofen 100 mg
RxNorm normalized name: ketoprofen 100 MG
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg b.i.d. for 5 days
Trial: NCT00810121
Drug: ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg b.i.d. for 5 days
Trial: NCT00373243
Drug: GW406381
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
Trial: NCT00787410
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg tablet, once daily, orally administered
Trial: NCT00385970
Drug: Krestin (PSK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
Trial: NCT01122199
Drug: RAD001 + AMG479
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
Trial: NCT02526381
Drug: Danlou Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
Trial: NCT02526381
Drug: Tongmai Yangxin Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
Trial: NCT01336738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (n=6), 0 mg, once daily for 84 days
Trial: NCT02753647
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02753647
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01101841
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
Trial: NCT01034917
Drug: Continue with the same antiretroviral regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue with the same antiretroviral regimen
Trial: NCT03003520
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
Trial: NCT03003520
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
Trial: NCT03853707
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01032629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule taken orally (by mouth) once daily
Trial: NCT03111992
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD1 antibody
Trial: NCT03111992
Drug: CJM112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-17A antibody
Trial: NCT03111992
Drug: LCL161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral small molecule SMAC-mimetic
Trial: NCT03371355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Matched with ISIS 703802)
Trial: NCT02722694
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All Subjects received backup Methotrexate treatment.
Trial: NCT01920802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID up to 4 weeks
Trial: NCT02472756
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
Trial: NCT03748940
Drug: LY3074828
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03748940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03748940
Drug: LY900021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04699994
Drug: FLOT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative FLOT therapy
Trial: NCT01973855
Drug: Western Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical cooling,Hydrocortisone
Trial: NCT01973855
Drug: TCM and Western Medicine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third Infectious diseases soup recipe
Trial: NCT04629560
Drug: Miracle Fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
Trial: NCT01773837
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (pill) p.o.
Trial: NCT03527576
Drug: NaCl 0.0308 MEQ/ML Injectable Solution
RxNorm normalized name: Glucose 43 MG/ML / NaCl 0.0308 MEQ/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of NaCl 0.9% before the surgery.
Trial: NCT00807950
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04095455
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
Trial: NCT02829879
Drug: 8% arginine/1450ppm sodium monofluorophosphate dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04035785
Drug: Kangfu Anti-inflammatory Suppository
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
Trial: NCT01816139
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
Trial: NCT01816139
Drug: WC3011 Estradiol Vaginal Cream
RxNorm normalized name: Estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
Trial: NCT02078388
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01943006
Drug: Placebo cream without active substance
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03239015
Drug: PD-1/L1 inhibitor plus anti-angiogenic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
Trial: NCT03662100
Drug: LY3074828
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02229734
Drug: Androgen Suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide 45mg every 6 months for a total of 18 months
Trial: NCT01360996
Drug: 3 mg DRSP/20 μg EE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
Trial: NCT00295269
Drug: Mythylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03883269
Drug: Clindamycin 1% topical lotion formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1% topical lotion formulation, BID, 4 weeks
Trial: NCT03883269
Drug: 70% topical ethanol solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% topical ethanol solution, BID, 4 weeks
Trial: NCT04522297
Drug: Nor-epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion norepinephrine
Trial: NCT00016458
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01264939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Trial: NCT01454076
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg tablets (Cycle 1 only)
Trial: NCT02653196
Drug: Keratinocyte Growth Factor
RxNorm normalized name: Keratinocyte growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KGF 60 mcg/kg IV: 6 doses
Trial: NCT02984176
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
Trial: NCT01823029
Drug: enteral nutrition.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01823029
Drug: injection of iron
RxNorm normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01302964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will receive placebo for duration of the study
Trial: NCT00136487
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02674412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
Trial: NCT02204254
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
Trial: NCT02433834
Drug: Serevent Diskus 50 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02433834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00190060
Drug: Transdermal testosterone gel (Testogel 1% )
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
Trial: NCT00190060
Drug: Matched transdermal placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched transdermal placebo gel, 50mg/d for 6 months
Trial: NCT03251326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT02209766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese
Trial: NCT00596011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo BID
Trial: NCT01099085
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg qd daily
Trial: NCT01099085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02720926
Drug: Xeloda,
RxNorm normalized name: Xeloda, 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
Trial: NCT02720926
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
Trial: NCT00796965
Drug: AZD7268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution/Capsule, Oral, once daily
Trial: NCT00796965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00239057
Drug: Enteric-Coated Mycophenolate Sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00024362
Drug: BBR 3464
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]
Trial: NCT04613180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo containing no active substance